Astria Therapeutics, Inc. (ATXS)
Automate Your Wheel Strategy on ATXS
With Tiblio's Option Bot, you can configure your own wheel strategy including ATXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATXS
- Rev/Share 0.0
- Book/Share 4.4912
- PB 1.621
- Debt/Equity 0.0183
- CurrentRatio 14.8851
- ROIC -0.4954
- MktCap 410846028.0
- FreeCF/Share -2.0
- PFCF -3.5414
- PE -3.6117
- Debt/Assets 0.0169
- DivYield 0
- ROE -0.3863
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | ATXS | H.C. Wainwright | -- | Buy | $16 | $20 | Sept. 17, 2025 |
| Initiation | ATXS | Cantor Fitzgerald | -- | Overweight | -- | $47 | April 29, 2025 |
| Initiation | ATXS | JMP Securities | -- | Mkt Outperform | -- | $26 | Jan. 31, 2025 |
News
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal antibody antagonist of OX40, in healthy subjects. STAR-0310 demonstrated a best-in-class half-life of up to 68 days, consistent with administration every six months, durable cytokine inhibition, and was we.
Read More
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 294.8% upside potential for Astria Therapeutics (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Thursday, September 4 at 3:20pm ET. A webcast of the presentation can be accessed at the following link: https://sqps.onstreamsecure.com/origin/enliven/players/E.
Read More
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Astria Therapeutics (ATXS) points to a 333.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
Published: June 06, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FRCPC, FAAAAI, Managing Director and Chair, Ottawa Allergy Research Corporation, will present combined i.
Read More
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025. Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from.
Read More
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the Eastern Allergy Conference (EAC) in Palm Beach, Florida on May 30, 2025. Raffi Tachdjian, M.D., Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, L.
Read More
Astria Therapeutics: A High-Conviction Bet On HAE
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation.
Read More
About Astria Therapeutics, Inc. (ATXS)
- IPO Date 2015-06-25
- Website https://www.astriatx.com
- Industry Biotechnology
- CEO Jill C. Milne
- Employees 78